EphemerisXResearch

Complete Response Letters

Polarean Inc.: Xenoview

What FDA's Complete Response Letters to the company say, in the letters' own words.

Complete Response Letter, Oct 5, 2021

1. The degree of polarization of xenon-129 hyperpolarized is a critical quality attribute of the drug component in your drug-device combination product.
Complete Response Letter · Oct 5, 2021 · p. 2Open the letter at p. 2 ↗CRL_NDA214375_20211005:p1:s20
Submit to the application the master batch record and executed batch records for production of xenon-129 hyperpolarized from hyperpolarizer © manufactured)
Complete Response Letter · Oct 5, 2021 · p. 3Open the letter at p. 3 ↗CRL_NDA214375_20211005:p1:s29
During a recent inspection of the Polarean Inc. (FEI:3010132318) manufacturing facility or this application, our field investigator conveyed deficiencies to the representative of he facility.
Complete Response Letter · Oct 5, 2021 · p. 4Open the letter at p. 4 ↗CRL_NDA214375_20211005:p2:s9
Satisfactory resolution of these deficiencies is required before this application may be approved.
Complete Response Letter · Oct 5, 2021 · p. 4Open the letter at p. 4 ↗CRL_NDA214375_20211005:p2:s10
During a recent inspection of the we manufacturing facility for this application, our field investigator conveyed deficiencies to he representative of the facility.
Complete Response Letter · Oct 5, 2021 · p. 4Open the letter at p. 4 ↗CRL_NDA214375_20211005:p2:s11

More Complete Response Letters

All companies in the CRL Tracker →

Updated Sep 30, 2026 · built from 283 companies in the EphemerisX knowledge graph. This page is regenerated as companies are added.